drugset / Trial / NCT02367937
PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study
NaSingle-groupOpen-label
Summary
The aim of the study is to evaluate the effect of PRC-4016 at steady state on the pharmacokinetics (PK) of cytochrome P450 (CYP) 3A substrates (midazolam, simvastatin), a CYP2C9 substrate (omeprazole) and a CYP2C19 substrate (flurbiprofen) in healthy male/female subjects.
Timeline
- Start
- 2014-08
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icosabutate | Small molecule | 600 mg | — |
Indications
No indication recorded.